Nls pharmaceutics announces early access program (eap) allowing patients with idiopathic hypersomnia to receive treatment with mazindol er

Named patient program (npp) enables physicians to prescribe the company's novel mazindol extended-release (er) formulation to patients who have failed approved therapies product sales through the npp are expected to be revenue-generating, with patient access anticipated to begin in q2 2022 zurich, switzerland / accesswire / march 28, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into an agreement with caligor coghlan pharma services (ccps) to administer a named patient program enabling european patients with idiopathic hypersomnia (ih) to have pre-approval access to treatment with the company's novel mazindol er formulation.
NLSP Ratings Summary
NLSP Quant Ranking